{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:15:37Z","timestamp":1790129737014,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T00:00:00Z","timestamp":1666396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jtho.2022.10.004","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T13:09:17Z","timestamp":1666703357000},"page":"169-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)"],"prefix":"10.1016","volume":"18","author":[{"given":"Jair","family":"Bar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Peled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiruyeh","family":"Schokrpur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana","family":"Wolner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Rotem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Aboubakar Nana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Derijcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Kian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Gantz-Sorotsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alona","family":"Zer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mor","family":"Moskovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Metro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakir","family":"Rottenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Calles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Hochmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristof","family":"Cuppens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Decoster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Limon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelamari","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoforos","family":"Astaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Bettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"H\u00e4fliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2022.10.004_bib1","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2022.10.004_bib2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2022.10.004_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2022.10.004_bib4","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2022.10.004_bib5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2022.10.004_bib6","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component","volume":"35","author":"Yang","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.10.004_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/1078-0432.CCR-05-1846","article-title":"Clinical course of patients with non\u2013small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib","volume":"12","author":"Riely","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2022.10.004_bib8","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jtho.2020.12.002","article-title":"Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations","volume":"16","author":"Passaro","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.10.004_bib9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.21037\/tlcr.2019.04.12","article-title":"Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment","volume":"8","author":"Zhang","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2022.10.004_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/JTO.0000000000000048","article-title":"Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q","volume":"9","author":"Watanabe","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.10.004_bib11","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","article-title":"Effectiveness of tyrosine kinase inhibitors on \u201cuncommon\u201d epidermal growth factor receptor mutations of unknown clinical significance in non\u2013small cell lung cancer","volume":"17","author":"Wu","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2022.10.004_bib12","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2022.10.004_bib13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","article-title":"Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases","volume":"15","author":"Yang","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.10.004_bib14","unstructured":"European Medicines Agency. Giotrif. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/giotrif. Accessed November 1, 2022."},{"key":"10.1016\/j.jtho.2022.10.004_bib15","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.19.00931","article-title":"Osimertinib for patients with non\u2013small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09)","volume":"38","author":"Cho","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2022.10.004_bib16","doi-asserted-by":"crossref","first-page":"9570","DOI":"10.1200\/JCO.2020.38.15_suppl.9570","article-title":"Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: a retrospective multicenter study","volume":"38","author":"Ji","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.10.004_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2022.01.014","article-title":"Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-treated advanced non-small-cell lung cancer","volume":"166","author":"Huang","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2022.10.004_bib18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/JTO.0000000000000504","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X\/L861Q\/S768I mutations","volume":"10","author":"Chiu","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.10.004_bib19","article-title":"Afatinib for the treatment of non-small cell lung cancer harboring uncommon EGFR mutations: an updated database of 1023 cases brief report","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2022.10.004_bib20","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2022.10.004_bib21","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-20-0103","article-title":"Osimertinib, an irreversible next-generation EGFR tyrosine kinase inhibitor, exerts antitumor activity in various preclinical NSCLC models harboring the uncommon EGFR mutations G719X or L861Q or S768I","volume":"19","author":"Floc\u2019h","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2022.10.004_bib22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jtho.2022.10.004_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan6566","article-title":"A\u00a0method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer","volume":"9","author":"Kohsaka","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2022.10.004_bib24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cllc.2017.05.016","article-title":"Outcomes of first-generation EGFR-TKIs against non-small-cell lung cancer harboring uncommon EGFR mutations: a post hoc analysis of the BE-POSITIVE study","volume":"19","author":"Pilotto","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2022.10.004_bib25","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.annonc.2022.02.225","article-title":"Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)","volume":"33","author":"Janning","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2022.10.004_bib26","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.10.004_bib27","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3390\/cancers14051143","article-title":"The role of TP53 mutations in EGFR-mutated non-small-cell lung cancer: clinical significance and implications for therapy","volume":"14","author":"Canale","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2022.10.004_bib28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2020.12.039","article-title":"The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance","volume":"153","author":"Fuchs","year":"2021","journal-title":"Lung Cancer"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086422018548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086422018548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:50:48Z","timestamp":1761562248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086422018548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1556086422018548"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2022.10.004","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2022.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}